The weakly ionized plasma flows in aerospace are commonly simulated by the single-fluid model,which cannot describe certain nonequilibrium phenomena by finite collisions of particles,decreasing the fidelity of the sol...The weakly ionized plasma flows in aerospace are commonly simulated by the single-fluid model,which cannot describe certain nonequilibrium phenomena by finite collisions of particles,decreasing the fidelity of the solution.Based on an alternative formulation of the targeted essentially non-oscillatory(TENO)scheme,a novel high-order numerical scheme is proposed to simulate the two-fluid plasmas problems.The numerical flux is constructed by the TENO interpolation of the solution and its derivatives,instead of being reconstructed from the physical flux.The present scheme is used to solve the two sets of Euler equations coupled with Maxwell's equations.The numerical methods are verified by several classical plasma problems.The results show that compared with the original TENO scheme,the present scheme can suppress the non-physical oscillations and reduce the numerical dissipation.展开更多
Summary What is already known about this topic?Previous research has primarily examined the issue of hepatitis B vaccine hesitancy in migrant workers and other adult populations.However,there is a lack of studies that...Summary What is already known about this topic?Previous research has primarily examined the issue of hepatitis B vaccine hesitancy in migrant workers and other adult populations.However,there is a lack of studies that have specifically investigated the prevalence of hepatitis B vaccine hesitancy among university students.What is added by this report?展开更多
Summary What is already known about this topic?As one of the populations at high risk of hepatitis B virus(HBV)infection,patients with chronic kidney disease(CKD)require rapid and effective development of hepatitis B ...Summary What is already known about this topic?As one of the populations at high risk of hepatitis B virus(HBV)infection,patients with chronic kidney disease(CKD)require rapid and effective development of hepatitis B surface antibodies(anti-HBs).What is added by this report?The short-course,high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen,achieving a seroconversion rate of 88.5%,a high-response rate of 64.1%,and anti-HBs geometric mean concentrations of 824.1 mIU/mL.What are the implications for public health practice?The short-course,high-dose regimen represents an effective rapid immunization strategy for CKD patients,particularly when administered prior to immunosuppressive therapy.This study provides compelling evidence for optimizing immunization protocols in the CKD population.展开更多
This study determined the effect of hepatitis B virus （HBV） replication in peripheral blood mononuclear cell （PBMC） from HBsAg-positive mothers on HBV intrauterine transmission. A total of 150 HBsAg- positive moth...This study determined the effect of hepatitis B virus （HBV） replication in peripheral blood mononuclear cell （PBMC） from HBsAg-positive mothers on HBV intrauterine transmission. A total of 150 HBsAg- positive mothers and their neonates were recruited in this study. Within 24 h after birth, HBV serological markers, serum HBV DNA, PBMC HBV relaxed circular DNA （rcDNA）, and covalently closed circular DNA （cccDNA） were measured in the HBsAg-positive mothers and their neonates before passive-active immune prophylaxis. The relationship between HBV replication in PBMC and HBV intrauterine transmission was examined through Chi- square test and logistic regression. The rate of HBV intrauterine transmission was 8.00% （12/150） in the 150 neonates born to HBsAg-positive mothers. The positivities of PBMC HBV rcDNA and cceDNA in the HBsAg- positive mothers were 36.67% （55/150） and 10% （15/150）, respectively. Maternal PBMC HBV cccDNA was a risk factor of HBV intrauterine transmission （OR = 6.003, 95% Ch 1.249-28.855）. Maternal serum HBeAg was a risk factor of PBMC HBV rcDNA （OR = 3.896, 95% CI： 1.929-7.876） and PBMC HBV cccDNA （OR = 3.74, 95% CI： 1.186--11.793） in the HBsAg-positive mothers. Administration of hepatitis B immune globulin was a protective factor ofPBMC HBV cccDNA （OR = 0.312, 95% CI： 0.102-0.954） during pregnancy. The positivity ofPBMC HBV rcDNA was related to that of cccDNA in the HBsAg-positive mothers （Zz= 5.087, P = 0.024）. This study suggests that PBMC is a reservoir of HBV and an extrahepatic site for virus replication and plays a critical role in HBV intrauterine transmission.展开更多
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a ran...Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a randomized parallel controlled trial for assessment of the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, aiming to determine an appropriate vaccination interval of the vaccine for high-risk occupational population.Methods: In an ongoing randomized, parallel, controlled phase IV trial between January and May 2021 in Taiyuan City, Shanxi Province, China, we randomly assigned the airport ground staff and public security officers aged 18 to 59 years to receive two doses of inactivated SARS-CoV-2 vaccine at 14 days, 21 days, or 28 days. The serum neutralizing antibody to live SARS-CoV-2 was performed at baseline and 28 days after immunization. Long-term data are being collected. The primary immunogenicity endpoints were neutralization antibody seroconversion and geometric mean titer (GMT) at 28 days after the second dose. Analysis of variance (ANOVA), chi-square, and logistic regression analysis were used for data analysis.Results: A total of 809 participants underwent randomization and received two doses of injections: 270, 270, 269 in the 0-14, 0-21, and 0-28 vaccination group, respectively. By day 28 after the second injection, SARS-CoV-2 neutralizing antibody of GMT was 98.4 (95%CI: 88.4-108.4) in the 0-14 group, which was significantly lower compared with 134.4 (95%CI: 123.1-145.7) in the 0-21 group (P < 0.001 vs 0-14 group) and 145.5 (95%CI: 131.3-159.6) in the 0-28 group (P < 0.001 vs 0-14 group), resulting in the seroconversion rates to neutralizing antibodies (GMT ≥ 16) of 100.0% for all three groups, respectively. The intention-to-treat (ITT) analysis yielded similar results. All reported adverse reactions were mild.Conclusions: Both a two-dose of inactivated SARS-CoV-2 vaccine at 0-21 days and 0-28 days regimens significantly improved SARS-CoV-2 neutralizing antibody level compared to the 0-14 days regimen in high-risk occupational population, with seroconversion rates of 100.0%.展开更多
基金Project supported by the National Natural Science Foundation of China(Nos.12072246,11972272,11872286)the National Numerical Wind Tunnel Project of China(No.NNW2020ZT3-A23)。
文摘The weakly ionized plasma flows in aerospace are commonly simulated by the single-fluid model,which cannot describe certain nonequilibrium phenomena by finite collisions of particles,decreasing the fidelity of the solution.Based on an alternative formulation of the targeted essentially non-oscillatory(TENO)scheme,a novel high-order numerical scheme is proposed to simulate the two-fluid plasmas problems.The numerical flux is constructed by the TENO interpolation of the solution and its derivatives,instead of being reconstructed from the physical flux.The present scheme is used to solve the two sets of Euler equations coupled with Maxwell's equations.The numerical methods are verified by several classical plasma problems.The results show that compared with the original TENO scheme,the present scheme can suppress the non-physical oscillations and reduce the numerical dissipation.
文摘Summary What is already known about this topic?Previous research has primarily examined the issue of hepatitis B vaccine hesitancy in migrant workers and other adult populations.However,there is a lack of studies that have specifically investigated the prevalence of hepatitis B vaccine hesitancy among university students.What is added by this report?
基金Supported by the National Science and Technology Major Project of the Ministry of Science and Technology of the People’s Republic of China under Grant[2018ZX10721202]the Key Research and Development Program of Lvliang under Grant[2020SHFZ52]the Key Research and Development Program of Science and Technology of Linfen under Grant[2136].
文摘Summary What is already known about this topic?As one of the populations at high risk of hepatitis B virus(HBV)infection,patients with chronic kidney disease(CKD)require rapid and effective development of hepatitis B surface antibodies(anti-HBs).What is added by this report?The short-course,high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen,achieving a seroconversion rate of 88.5%,a high-response rate of 64.1%,and anti-HBs geometric mean concentrations of 824.1 mIU/mL.What are the implications for public health practice?The short-course,high-dose regimen represents an effective rapid immunization strategy for CKD patients,particularly when administered prior to immunosuppressive therapy.This study provides compelling evidence for optimizing immunization protocols in the CKD population.
文摘This study determined the effect of hepatitis B virus （HBV） replication in peripheral blood mononuclear cell （PBMC） from HBsAg-positive mothers on HBV intrauterine transmission. A total of 150 HBsAg- positive mothers and their neonates were recruited in this study. Within 24 h after birth, HBV serological markers, serum HBV DNA, PBMC HBV relaxed circular DNA （rcDNA）, and covalently closed circular DNA （cccDNA） were measured in the HBsAg-positive mothers and their neonates before passive-active immune prophylaxis. The relationship between HBV replication in PBMC and HBV intrauterine transmission was examined through Chi- square test and logistic regression. The rate of HBV intrauterine transmission was 8.00% （12/150） in the 150 neonates born to HBsAg-positive mothers. The positivities of PBMC HBV rcDNA and cceDNA in the HBsAg- positive mothers were 36.67% （55/150） and 10% （15/150）, respectively. Maternal PBMC HBV cccDNA was a risk factor of HBV intrauterine transmission （OR = 6.003, 95% Ch 1.249-28.855）. Maternal serum HBeAg was a risk factor of PBMC HBV rcDNA （OR = 3.896, 95% CI： 1.929-7.876） and PBMC HBV cccDNA （OR = 3.74, 95% CI： 1.186--11.793） in the HBsAg-positive mothers. Administration of hepatitis B immune globulin was a protective factor ofPBMC HBV cccDNA （OR = 0.312, 95% CI： 0.102-0.954） during pregnancy. The positivity ofPBMC HBV rcDNA was related to that of cccDNA in the HBsAg-positive mothers （Zz= 5.087, P = 0.024）. This study suggests that PBMC is a reservoir of HBV and an extrahepatic site for virus replication and plays a critical role in HBV intrauterine transmission.
基金The study was supported by the COVID-19 Project of Shanxi Provincial Finance, and the Project of Shanxi Provincial Key Laboratory for major infectious disease response.
文摘Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a randomized parallel controlled trial for assessment of the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, aiming to determine an appropriate vaccination interval of the vaccine for high-risk occupational population.Methods: In an ongoing randomized, parallel, controlled phase IV trial between January and May 2021 in Taiyuan City, Shanxi Province, China, we randomly assigned the airport ground staff and public security officers aged 18 to 59 years to receive two doses of inactivated SARS-CoV-2 vaccine at 14 days, 21 days, or 28 days. The serum neutralizing antibody to live SARS-CoV-2 was performed at baseline and 28 days after immunization. Long-term data are being collected. The primary immunogenicity endpoints were neutralization antibody seroconversion and geometric mean titer (GMT) at 28 days after the second dose. Analysis of variance (ANOVA), chi-square, and logistic regression analysis were used for data analysis.Results: A total of 809 participants underwent randomization and received two doses of injections: 270, 270, 269 in the 0-14, 0-21, and 0-28 vaccination group, respectively. By day 28 after the second injection, SARS-CoV-2 neutralizing antibody of GMT was 98.4 (95%CI: 88.4-108.4) in the 0-14 group, which was significantly lower compared with 134.4 (95%CI: 123.1-145.7) in the 0-21 group (P < 0.001 vs 0-14 group) and 145.5 (95%CI: 131.3-159.6) in the 0-28 group (P < 0.001 vs 0-14 group), resulting in the seroconversion rates to neutralizing antibodies (GMT ≥ 16) of 100.0% for all three groups, respectively. The intention-to-treat (ITT) analysis yielded similar results. All reported adverse reactions were mild.Conclusions: Both a two-dose of inactivated SARS-CoV-2 vaccine at 0-21 days and 0-28 days regimens significantly improved SARS-CoV-2 neutralizing antibody level compared to the 0-14 days regimen in high-risk occupational population, with seroconversion rates of 100.0%.
